Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Expands Indication For Pipeline Flex Embolization Device

Executive Summary

Medtronic's Pipeline Flex device is now labeled for treating patients with small or medium wide-necked brain aneurysms following US FDA approval for an expanded indication.

You may also be interested in...



Market Snapshot: Flow Diversion Sees Highest Growth Among Neurointerventional Embolization Systems

Our infographic spotlights key trends in the global market for cerebral aneurysm and arteriovenous malformation (AVM) embolization systems, which is expected to reach $1.2bn by 2022, a CAGR of 3.9% from $975m in 2017. Among the growth drivers is the improvement of imaging screening techniques in developed nations. While this has resulted in increased intervention for cerebral aneurysm and AVM embolization, routine screening is not practiced, even in developed nations. Embolic coils accounted for the majority of sales with an estimated 73% market share. Meanwhile, a growing number of improved and premium-priced products such coil-assisted stent products and advanced embolic coil designs and flow diversion products are driving up the total value of the market.

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.

Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs

Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel